www.leadleo.com 2025年中国生物创新药市场跟踪报告： 呋喹替尼7月市场动向 2025 China Biopharmaceutical Innovation Market Tracking Report: Market Trends for Fitinib in July 2025年中国バイオ医薬品イノベーション市場追跡レポート：7月時点のフィチニブ市場動向 概览标签：呋喹替尼、结直肠癌、和黄医药 作者：何婉怡 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均 系头豹研究院独有的高度机密性文件（在报告中另行标明出处者除外 、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述 约定的行为发生，头豹研究院保留采取法律措施，追究相关人员责任 的权利。头豹研究院开展的所有商业活动均使用"头豹研究院"或"头豹 "的商号、商标，头豹研究院无任何前述名称之外的其他分支机构， 也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 1 ©2025 LeadLeo ）。 ，任何人不得以任何方式擅自复制 www.leadleo.com 400-072-5588 #6C0000 #7C0000 ...

Core Insights - Intensity Therapeutics (INTS.US) announced significant results from its Phase 1/2 clinical trial for the candidate drug INT230-6, leading to a nearly 395% surge in stock price [1] Group 1: Drug Mechanism and Clinical Data - INT230-6 operates by directly injecting into tumors, facilitating the diffusion of cisplatin and vinblastine sulfate, along with a cell-penetrating enhancer molecule (SHAO) [1] - The trial involved 64 patients across over 20 cancer types, all of whom had undergone extensive prior treatments, achieving a disease control rate of 75% [1] - The median overall survival (mOS) for the entire patient group was 11.9 months, with a notable 21.3 months for the metastatic sarcoma subgroup [1] - No grade 4 or 5 treatment-related adverse events were reported, with only 7 patients experiencing grade 3 adverse events, and no dose-limiting toxicities observed [1] Group 2: Market Reaction and Future Plans - The market reacted positively to the trial data, indicating strong interest in the field of solid tumor treatments [2] - Intensity Therapeutics has partnered with Merck (MRK.US) and Bristol-Myers Squibb (BMY.US) to explore combination therapies with Keytruda and Yervoy [2] - A conference call is scheduled for October 31 to discuss the clinical trial results, which have been published in the journal eBioMedicine [2]